Figure S2 from SDP-LIV1, a Novel and Optimized LIV-1 Antibody–Drug Conjugate Demonstrating Superior Antitumor Efficacy and a Favorable Safety Profile for the Treatment of Solid Tumors
Abstract
Figure S2 shows the binding kinetics of SDP-LIV1-Ab, SDP-LIV1, and BMK-vcMMAE to LIV-1 of Human, Rhesus and Rat.
Fields of Study & Subjects
Monoclonal and Polyclonal Antibodies Research
Radiopharmaceutical Chemistry and Applications
Protein Degradation and Inhibitors
Publication details
- Publication date
- 4 February 2026